News Column

FUJIFILM Announces FDA 510k Clearance for New Breast Imaging Solution: Aspire Cristalle

July 10, 2014



By a News Reporter-Staff News Editor at Women's Health Weekly -- FUJIFILM Medical Systems U.S.A., Inc., a global leader in technology innovation with the largest worldwide install base of digital mammography systems, announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) of the Aspire Cristalle. The Aspire Cristalle resets the bar in digital mammography, combining innovative detector engineering with well thought out patient focused ergonomics, resulting in faster more confident diagnosis for clinicians and exceptional patient comfort. First commercialized in Asia and Europe, the Aspire Cristalle has taken hold of our customers' imagination and challenged the status quo in breast imaging technology across the globe (see also FUJIFILM Medical Systems U.S.A., Inc.).

"Aspire Cristalle nicely represents our latest culmination of imaging innovation and attention to every detail in design," said Rob Fabrizio, director of marketing and product development, Digital x-ray and Women's Health, FUJIFILM Medical Systems U.S.A., Inc. "The Aspire Cristalle will deliver brilliant images with gentle dose, while redefining the patient experience through a notably more comfortable exam."

Keywords for this news article include: Technology, Breast Cancer Screening, FUJIFILM Medical Systems U.S.A. Inc., Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Women's Health Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters